Want to see AIDX full AI Analyst Report?
AIDX Stock Chart & Stats
$0.63
--
Market closed
$0.63
--
Day’s Range― - ―
52-Week Range$0.40 - $50.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)79.93K
Market Cap
$6.02M
Enterprise Value$4.30
Total Cash (Recent Filing)$4.55M
Total Debt (Recent Filing)$572.45K
Price to Earnings (P/E)―
Beta2.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,770,303
10 Day Avg. Volume47,694
30 Day Avg. Volume79,929
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)-7.76K
Price to Sales (P/S)72.96
P/FCF Ratio-0.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Revenue ReboundThe sharp 2025 revenue rebound indicates that demand for the company’s laboratory testing and diagnostic services can recover meaningfully after contraction. If maintained, stronger sales would improve operating leverage, support customer adoption, and provide a broader base for rebuilding sustainable earnings.
Improved Gross MarginThe improvement in gross margin shows that the revenue base became more economically attractive year over year. Sustained margin expansion could strengthen each test or service sold, improve the company’s ability to absorb operating costs, and support eventual progress toward positive operating profitability.
Infection-Control Testing FocusThe company operates in a business area tied to infection prevention and control, where customers use microbial and pathogen testing to manage contamination risk. This specialized service focus can support recurring monitoring demand and gives the business a clearly defined role in healthcare and other relevant settings.
Bears Say
Persistent UnprofitabilityPersistent negative operating and net margins show that the current cost structure is not scaling with revenue, even after the 2025 sales rebound. Without further cost discipline or continued gross-margin improvement, revenue growth may not translate into durable earnings and could leave the business reliant on outside funding.
Severe Cash BurnSustained negative operating and free cash flow indicate that the business is not currently funding itself through operations. The especially large 2025 cash burn increases funding needs, reduces flexibility to invest in growth, and makes financial stability more dependent on obtaining external capital.
Negative Equity And High DebtExtremely high debt combined with negative stockholders’ equity materially weakens the balance sheet. This structure limits financial flexibility, increases refinancing and solvency risk, and can constrain the company’s ability to fund diagnostic expansion or withstand further operating volatility.
20/20 Biolabs, Inc. News
AIDX FAQ
What was 20/20 Biolabs, Inc.’s price range in the past 12 months?
20/20 Biolabs, Inc. lowest stock price was $0.40 and its highest was $50.00 in the past 12 months.
What is 20/20 Biolabs, Inc.’s market cap?
20/20 Biolabs, Inc.’s market cap is $6.02M.
When is 20/20 Biolabs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 20/20 Biolabs, Inc.’s earnings last quarter?
Currently, no data Available
Is 20/20 Biolabs, Inc. overvalued?
According to Wall Street analysts 20/20 Biolabs, Inc.’s price is currently Overvalued.
Does 20/20 Biolabs, Inc. pay dividends?
20/20 Biolabs, Inc. does not currently pay dividends.
What is 20/20 Biolabs, Inc.’s EPS estimate?
20/20 Biolabs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 20/20 Biolabs, Inc. have?
20/20 Biolabs, Inc. has 12,770,303 shares outstanding.
What happened to 20/20 Biolabs, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 20/20 Biolabs, Inc.?
Currently, no hedge funds are holding shares in AIDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
20/20 Biolabs, Inc.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Technical Analysis
Biomerica
―
Co-Diagnostics
―
Lucid Diagnostics
―
Bluejay Diagnostics
―
Heart Test Laboratories, Inc.
―